Mateon’s ovarian cancer treatment CA4P shows favorable results in Focus study

CA4P is Mateon’s investigational drug, as well as potent and tubulin-binding vascular disrupting agent (VDA).

Focus study is assessing CA4P in combination with bevacizumab and physician's choice chemotherapy in patients with platinum resistant ovarian cancer (prOC).

The study has been designed to assess whether the addition of CA4P improves progression-free survival (PFS), which is the primary endpoint of the study. It is also evaluating objective response rate (ORR) and other measures.

According to the company, the PFS continues to favor the CA4P group with a 1.68 month increase in median PFS for the patients receiving CA4P compared to control (6.64 months versus 4.96 months.)

Patients recruited in the trial are securing either CA4P or placebo plus the current standard-of-care for platinum-resistant ovarian cancer bevacizumab and chemotherapy.

The current interim analysis is based on initial results from the first 40 patients in the study who were treated for at least two months or discontinued from the trial. The phase 2 portion of the trial recruited 91 patients.

The firm also intends to assess CA4P to treat other tumor types such as neuroendocrine tumors (NETs), glioblastoma multiforme (GBM), hepatocellular carcinoma, and gastric cancer.

Mateon Therapeutics president and CEO Dr William Schwieterman said: "We are encouraged that early data on the primary endpoint of the study continue to favor CA4P and that our investigational drug remains well tolerated.

“There is a large unmet medical need in the ovarian cancer market as patients with prOC have low survival rates and few treatment options.”

Image: Focus study is evaluating CA4P in combination with bevacizumab and physician's choice chemotherapy in patients with platinum resistant ovarian cancer. Photo: courtesy of jk1991 / FreeDigitalPhotos.net.